<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bmjour</journal-id><journal-title-group><journal-title xml:lang="ru">Байкальский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Baikal Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-0715</issn><publisher><publisher-name>Irkutsk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.57256/2949-0715-2024-2-11-24</article-id><article-id custom-type="elpub" pub-id-type="custom">bmjour-221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Научные обзоры литературы</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Scientific literature reviews</subject></subj-group></article-categories><title-group><article-title>РАСПРОСТРАНЕННОСТЬ, КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ И РОЛЬ ГЕНЕТИЧЕСКИХ ФАКТОРОВ В РАЗВИТИИ МЕТАБОЛИЧЕСКИ АССОЦИИРОВАННОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ (ОБЗОР ЛИТЕРАТУРЫ)</article-title><trans-title-group xml:lang="en"><trans-title>ROLE OF GENETIC FACTORS IN THE DEVELOPMENT OF METABOLICALLY ASSOCIATED FATTY LIVER DISEASE (LITERATURE REVIEW)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7525-2657</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткачук</surname><given-names>Елена Анатольевна</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachuk</surname><given-names>Elena Anatolievna</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., доцент, профессор кафедры патологической физиологии и клинической лабораторной диагностики ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1; старший научный сотрудник ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека», Россия, 664003, г. Иркутск, ул. Тимирязева, 16; ведущий научный сотрудник ФГБНУ «Восточно-Сибирский институт медико-экологических исследований», Россия, 665826, г. Ангарск, микрорайон 12а, дом 3</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Associate Professor, Professor of the Department of Pathological Physiology and Clinical Laboratory Diagnostics, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1; senior researcher at the «Scientific Center for Problems of Family Health and Human Reproduction», Russia, 664003, Irkutsk, st. Timiryazeva, 16; leading researcher at the «East Siberian Institute of Medical and Environmental Research», Russia, 665826, Angarsk, microdistrict 12a, building 3</p></bio><email xlink:type="simple">zdorowie38@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7530-0716</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семинский</surname><given-names>Игорь Жанович</given-names></name><name name-style="western" xml:lang="en"><surname>Seminsky</surname><given-names>Igor Janovich</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующий кафедрой патологической физиологии и клинической лабораторной диагностики ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), professor, chief of the Department of Pathological Physiology and Clinical Laboratory Diagnostics, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0083-8845</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлова</surname><given-names>Наталья Михайловна</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlova</surname><given-names>Natalya M</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой факультетской терапии ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Department of Faculty Therapy, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3135-4616</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малов</surname><given-names>Сергей Игоревич</given-names></name><name name-style="western" xml:lang="en"><surname>Malov</surname><given-names>Sergey I</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проректор по научной работе ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Vice-Rector for Scientific Work, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1427-4734</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Астахова</surname><given-names>Татьяна Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Astakhova</surname><given-names>Tatyana A</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., врач-генетик ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека», Россия, 664003, г. Иркутск, ул. Тимирязева, 16</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), geneticist of the «Scientific Center for Problems of Family Health and Human Reproduction», Russia, 664003, Irkutsk, st. Timiryazeva, 16</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абрамова</surname><given-names>Анастасия Николаевна</given-names></name><name name-style="western" xml:lang="en"><surname>Abramova</surname><given-names>Anastasia N</given-names></name></name-alternatives><bio xml:lang="ru"><p>ординатор кафедры факультетской терапии ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>resident of the department of faculty therapy, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0978-7991</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Убушеева</surname><given-names>Раиса Георгиевна</given-names></name><name name-style="western" xml:lang="en"><surname>Ubusheeva</surname><given-names>Raisa G</given-names></name></name-alternatives><bio xml:lang="ru"><p>ординатор кафедры факультетской терапии ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>resident of the department of faculty therapy, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России&#13;
ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека»&#13;
ФГБНУ «Восточно-Сибирский институт медико-экологических исследований»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBEI HE IGMU MINISTRY OF HEALTH OF Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Irkutsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff xml:lang="ru" id="aff-3"><institution>ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России</institution><country>Russian Federation</country></aff><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО ИГМУ Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Irkutsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Center for Problems of Family Health and Human Reproduction</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>resident of the department of faculty therapy, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>06</month><year>2024</year></pub-date><volume>3</volume><issue>2</issue><fpage>11</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ткачук Е.А., Семинский И.Ж., Козлова Н.М., Малов С.И., Астахова Т.А., Абрамова А.Н., Убушеева Р.Г., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ткачук Е.А., Семинский И.Ж., Козлова Н.М., Малов С.И., Астахова Т.А., Абрамова А.Н., Убушеева Р.Г.</copyright-holder><copyright-holder xml:lang="en">Tkachuk E.A., Seminsky I.J., Kozlova N.M., Malov S.I., Astakhova T.A., Abramova A.N., Ubusheeva R.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bmjour.ru/jour/article/view/221">https://www.bmjour.ru/jour/article/view/221</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Заболевания печени являются серьезной социальной проблемой. Изучение патогенетических механизмов развития этих заболеваний, поиск методов лечения, способных кардинально улучшить состояние пациента и остановить развитие заболевания является весьма актуальным и востребованным. Диагностика и лечение такого распространенного заболевания как неалкогольная жировая болезнь печения является одним из актуальных вопросов современной медицины.</p></sec><sec><title>Цель</title><p>Цель: Провести анализ доступных литературных источников о распространенности, клинических  проявлениях и роли генетических факторов этиопатогенезе неалкогольной жировой болезни печени.</p></sec><sec><title>Результаты исследования</title><p>Результаты исследования. В обзоре представлены генетические аспекты развития метаболически ассоциированной жировой болезни печени (новое название) или неалкогольной жировой болезни печени (общепринятое название). Рассмотрены ведущие синдромы, сопровождающие развитие заболевания: астенический синдром, синдром нарушения циркадиадных ритмов ("циркадный" синдром), синдром обструктивного апноэ во сне, синдром цитолиза, синдром инсулинорезистентности, метаболический синдром, болевой синдром, диспепсический синдром, синдром раздраженного кишечника, синдром избыточного бактериального роста, синдром гепатомегалии и/или спленомегалии, синдром фиброза, синдром поликистозных яичников. Освещены основные коморбидные состояния: со стороны печени – гепатоцеллюлярная карцинома, цирроз печени, внепеченочные осложнения – ожирение, сахарный диабет 2 типа, сердечно-сосудистые нарушения – атеросклероз, со стороны почек – хроническая почечная болезнь и др. Приведены данные о генах, влияющих на развитие заболевания: PNPLA3, TM6SF2, MBOAT7, HSD17B13, GCKR, HFE, CP, INS, PPARG, CYP11A, AR, ENPP1,  <ext-link xlink:href="https://www.genenames.org/tools/search/#!/genes?query=MTTP" ext-link-type="uri">MTTP</ext-link>.</p></sec><sec><title>Заключение</title><p>Заключение. Изучение этиологических причин (генетических полиморфизмов) неалкогольной жировой болезни печени является основной задачей на пути решения проблем эффективной помощи пациентам. Изучение генетических полиморфизмов, связанных с неалкогольной болезнью печени и их роли в патогенезе должно уделяться больше внимания при разработке современных методов лечения.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Liver diseases are a serious social problem. The study of the pathogenetic mechanisms of the development of these diseases, the search for treatment methods that can radically improve the patient’s condition and stop the development of the disease is very relevant and in demand.</p></sec><sec><title>Aim</title><p>Aim: to conduct a literature review of currently known genetic factors in the etiology of non-alcoholic liver disease.</p></sec><sec><title> Research results</title><p> Research results. The review presents the genetic aspects of the development of metabolically associated fatty liver disease (new name) or non-alcoholic fatty liver disease (common name). The leading syndromes accompanying the development of the disease are considered: asthenic syndrome, circadian rhythm disturbance syndrome ("circadian" syndrome), obstructive sleep apnea syndrome, cytolysis syndrome, insulin resistance syndrome, metabolic syndrome, pain syndrome, dyspeptic syndrome, irritable bowel syndrome, bacterial overgrowth syndrome growth, hepatomegaly and/or splenomegaly syndrome, fibrosis syndrome, polycystic ovary syndrome. The main comorbid conditions are covered: from the liver - hepatocellular carcinoma, cirrhosis of the liver, extrahepatic complications - obesity, type 2 diabetes mellitus, cardiovascular disorders - atherosclerosis, from the kidneys - chronic renal disease, etc. Data on genes affecting the development of diseases: PNPLA3, TM6SF2, MBOAT7, HSD17B13, GCKR, HFE, CP, INS, PPARG, CYP11A, AR, ENPP1, MTTP.</p></sec><sec><title>Conclusion</title><p>Conclusion. Studying the etiological causes (genetic polymorphisms) of non-alcoholic fatty liver disease is the main task towards solving the problems of effective patient care.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>метаболически ассоциированная жировая болезнь печени</kwd><kwd>гены PNPLA3</kwd><kwd>TM6SF2</kwd><kwd>MBOAT7</kwd><kwd>HSD17B13</kwd><kwd>GCKR</kwd><kwd>HFE</kwd><kwd>CP</kwd><kwd>INS</kwd><kwd>PPARG</kwd><kwd>CYP11A</kwd><kwd>AR</kwd><kwd>ENPP1</kwd><kwd>MTTP.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>metabolically associated fatty liver disease</kwd><kwd>genes PNPLA3</kwd><kwd>TM6SF2</kwd><kwd>MBOAT7</kwd><kwd>HSD17B13</kwd><kwd>GCKR</kwd><kwd>HFE</kwd><kwd>CP</kwd><kwd>INS</kwd><kwd>PPARG</kwd><kwd>CYP11A</kwd><kwd>AR</kwd><kwd>ENPP1</kwd><kwd>MTTP.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chiang D.J., McCullough A.J. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis. 2014;18(1):157-163. DOI:10.1016/j.cld.2013.09.006.</mixed-citation><mixed-citation xml:lang="en">Chiang D.J., McCullough A.J. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis. 2014;18(1):157-163. DOI:10.1016/j.cld.2013.09.006.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации. М.: ООО «Издательский дом «М-Вести»;2009 [Ivashkin V.T., Drapkina O.M., Shulpekova Yu.O. Diagnosis and treatment of non-alcoholic fatty liver disease. Guidelines. M.:«Publishing House «M-Vesti»; 2009 (In Russian)].</mixed-citation><mixed-citation xml:lang="en">Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации. М.: ООО «Издательский дом «М-Вести»;2009 [Ivashkin V.T., Drapkina O.M., Shulpekova Yu.O. Diagnosis and treatment of non-alcoholic fatty liver disease. Guidelines. M.:«Publishing House «M-Vesti»; 2009 (In Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;4:32-38 [Drapkina O.M., Ivashkin V.T. Epidemiological features of non-alcoholic fatty liver disease in Russia (Results of an open multicenter prospective observational study DIREG L 01903). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;4:32-38 (In Russian)]. http://old-gastro-j.ru/files/_2014_4_s4_1417549799.pdf [дата доступа: 10.05.2024].</mixed-citation><mixed-citation xml:lang="en">Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;4:32-38 [Drapkina O.M., Ivashkin V.T. Epidemiological features of non-alcoholic fatty liver disease in Russia (Results of an open multicenter prospective observational study DIREG L 01903). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;4:32-38 (In Russian)]. http://old-gastro-j.ru/files/_2014_4_s4_1417549799.pdf [дата доступа: 10.05.2024].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Евстифеева С.Е., Шальнова С.А., Куценко В.А. и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356 [Evstifeeva S.E., Shalnova S.A., Kutsenko V.A. et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356 (In Russian)]. DOI:10.15829/1728-8800-2022-3356</mixed-citation><mixed-citation xml:lang="en">Евстифеева С.Е., Шальнова С.А., Куценко В.А. и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356 [Evstifeeva S.E., Shalnova S.A., Kutsenko V.A. et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356 (In Russian)]. DOI:10.15829/1728-8800-2022-3356</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285. DOI:10.1111/j.1365-2036.2011.04724.x</mixed-citation><mixed-citation xml:lang="en">Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285. DOI:10.1111/j.1365-2036.2011.04724.x</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Estes C., Anstee Q.M., Arias-Loste M.T. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Hepatology. 2018;69:896-904. DOI:10.1016/j.jhep.2018.05.036.</mixed-citation><mixed-citation xml:lang="en">Estes C., Anstee Q.M., Arias-Loste M.T. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Hepatology. 2018;69:896-904. DOI:10.1016/j.jhep.2018.05.036.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Пальгова Л.К., Барановский А.Ю., Ушакова Т.И. и др. Эпидемиологические особенности неалкогольной жировой болезни печени в Cеверо-Западном регионе России (результаты открытого многоцентрового проспективного исследования DIREG 2). Вестник СПбГУ. Медицина. 2017; 12(2):118–135 [Palgova L.K., Baranovsky A.Yu., Ushakova T.I. et al. Epidemiological features of non-alcoholic fatty liver disease in the North-West region of Russia (results of an open multicenter prospective study DIREG 2). Bulletin of St. Petersburg State University. Medicine. 2017;12(2):118–135 (In Russian)]. DOI:10.21638/11701/spbu11.2017.201</mixed-citation><mixed-citation xml:lang="en">Пальгова Л.К., Барановский А.Ю., Ушакова Т.И. и др. Эпидемиологические особенности неалкогольной жировой болезни печени в Cеверо-Западном регионе России (результаты открытого многоцентрового проспективного исследования DIREG 2). Вестник СПбГУ. Медицина. 2017; 12(2):118–135 [Palgova L.K., Baranovsky A.Yu., Ushakova T.I. et al. Epidemiological features of non-alcoholic fatty liver disease in the North-West region of Russia (results of an open multicenter prospective study DIREG 2). Bulletin of St. Petersburg State University. Medicine. 2017;12(2):118–135 (In Russian)]. DOI:10.21638/11701/spbu11.2017.201</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Мишина Е.Е., Майоров А.Ю., Богомолов П.О. и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017;20(5):335-342 [Mishina E.E., Mayorov A.Y., Bogomolov P.O., Matsievich M.V., Kokina K.Y., Bogolyubova A.V. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343 (In Russian)]. DOI: 10.14341/DM9372</mixed-citation><mixed-citation xml:lang="en">Мишина Е.Е., Майоров А.Ю., Богомолов П.О. и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017;20(5):335-342 [Mishina E.E., Mayorov A.Y., Bogomolov P.O., Matsievich M.V., Kokina K.Y., Bogolyubova A.V. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343 (In Russian)]. DOI: 10.14341/DM9372</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Бутрова С.А., Елисеева А.Ю. Неалкогольная жировая болезнь печени: актуальные проекты. Ожирение и метаболизм. 2007;4(2):2-7 [Butrova S.A., Eliseeva A.Yu. Nealkogol'naya zhirovaya bolezn' pecheni: aktual'nye proekty. Obesity and metabolism. 2007;4(2):2-7 (In Russian)]. DOI:10.14341/2071-8713-5155</mixed-citation><mixed-citation xml:lang="en">Бутрова С.А., Елисеева А.Ю. Неалкогольная жировая болезнь печени: актуальные проекты. Ожирение и метаболизм. 2007;4(2):2-7 [Butrova S.A., Eliseeva A.Yu. Nealkogol'naya zhirovaya bolezn' pecheni: aktual'nye proekty. Obesity and metabolism. 2007;4(2):2-7 (In Russian)]. DOI:10.14341/2071-8713-5155</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеева Л. Н., Болотова Е. В. Распространенность неалкогольной жировой болезни печени среди пациентов амбулаторно-поликлинического звена в Краснодаре. Доктор.Ру. 2018;7(151):25–29 [Eliseeva L. N., Bolotova E. V. Incidence of Nonalcoholic Fatty Liver Disease in Outpatient Patients in Krasnodar. Doctor.Ru. 2018; 7(151): 25–29 (In Russian)]. DOI:10.31550/1727-2378-2018-151-7-25-29</mixed-citation><mixed-citation xml:lang="en">Елисеева Л. Н., Болотова Е. В. Распространенность неалкогольной жировой болезни печени среди пациентов амбулаторно-поликлинического звена в Краснодаре. Доктор.Ру. 2018;7(151):25–29 [Eliseeva L. N., Bolotova E. V. Incidence of Nonalcoholic Fatty Liver Disease in Outpatient Patients in Krasnodar. Doctor.Ru. 2018; 7(151): 25–29 (In Russian)]. DOI:10.31550/1727-2378-2018-151-7-25-29</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Буеверов А.О. Неалкогольная жировая болезнь печени как мультидисциплинарная патология. М.: Видокс; 2017 [Drapkina O. M., Bueverov A.O. Nealkogol’naya zhirova-ya bolezn’ pecheni kak mul’tidistciplinarnaya patologiya [Non-alcoholic fatty liver disease as a multidisciplinary pathology]. M.: Vidoks; 2017 (In Russian)].</mixed-citation><mixed-citation xml:lang="en">Драпкина О.М., Буеверов А.О. Неалкогольная жировая болезнь печени как мультидисциплинарная патология. М.: Видокс; 2017 [Drapkina O. M., Bueverov A.O. Nealkogol’naya zhirova-ya bolezn’ pecheni kak mul’tidistciplinarnaya patologiya [Non-alcoholic fatty liver disease as a multidisciplinary pathology]. M.: Vidoks; 2017 (In Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kelley C.E., Brown A.J., Diehl A.M., Setji T.L. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20(39):14172-14184. DOI:10.3748/wjg.v20.i39.14172</mixed-citation><mixed-citation xml:lang="en">Kelley C.E., Brown A.J., Diehl A.M., Setji T.L. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20(39):14172-14184. DOI:10.3748/wjg.v20.i39.14172</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей Российского общества по изучению печени. Под ред. Ивашкина В.Т. М.:МЕДпресс-информ;2015 [Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors of the Russian Society for the Study of the Liver. Ed. Ivashkina V.T. M.: MEDpress-inform; 2015 (In Russian)].</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей Российского общества по изучению печени. Под ред. Ивашкина В.Т. М.:МЕДпресс-информ;2015 [Diagnosis and treatment of non-alcoholic fatty liver disease: guidelines for doctors of the Russian Society for the Study of the Liver. Ed. Ivashkina V.T. M.: MEDpress-inform; 2015 (In Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Бутрова С.А. Синдром поликистозных яичников и метаболический синдром. Ожирение и метаболизм. 2006;3(1):30-40 [Dedov I.I., Butrova S.A. Sindrom polikistoznykh yaichnikov i metabolicheskiy sindrom. Obesity and metabolism. 2006;3(1):30-40 (In Russian)]. DOI:10.14341/2071-8713-4940</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Бутрова С.А. Синдром поликистозных яичников и метаболический синдром. Ожирение и метаболизм. 2006;3(1):30-40 [Dedov I.I., Butrova S.A. Sindrom polikistoznykh yaichnikov i metabolicheskiy sindrom. Obesity and metabolism. 2006;3(1):30-40 (In Russian)]. DOI:10.14341/2071-8713-4940</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cheungpasitporn W., Thongprayoon C., O'Corragain O.A. et al. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton). 2014;19(12):791-797. DOI:10.1111/nep.12343.</mixed-citation><mixed-citation xml:lang="en">Cheungpasitporn W., Thongprayoon C., O'Corragain O.A. et al. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton). 2014;19(12):791-797. DOI:10.1111/nep.12343.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Baguet J.P., Barone-Rochette G., Tamisier R. et al. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012;9(12):679-688. DOI:10.1038/nrcardio.2012.141.</mixed-citation><mixed-citation xml:lang="en">Baguet J.P., Barone-Rochette G., Tamisier R. et al. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012;9(12):679-688. DOI:10.1038/nrcardio.2012.141.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Parati G., Lombardi C., Hedner J. et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30(4):633-646. DOI:10.1097/HJH.0b013e328350e53b</mixed-citation><mixed-citation xml:lang="en">Parati G., Lombardi C., Hedner J. et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30(4):633-646. DOI:10.1097/HJH.0b013e328350e53b</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Eshraghian A., Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014;20(25):8102-8109. DOI:10.3748/wjg.v20.i25.8102</mixed-citation><mixed-citation xml:lang="en">Eshraghian A., Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014;20(25):8102-8109. DOI:10.3748/wjg.v20.i25.8102</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Носов А.Е., Зенина М.Т., Горбушина О.Ю. и др. Значимость клинико-лабораторных индексов в диагностике неалкогольной жировой болезни печени. Терапевтический архив. 2021;93(8):883-889 [Nosov A.E., Zenina M.T., Gorbushina O.Yu. et al. Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):883–889 (In Russian)]. DOI: 10.26442/00403660.2021.08.200973</mixed-citation><mixed-citation xml:lang="en">Носов А.Е., Зенина М.Т., Горбушина О.Ю. и др. Значимость клинико-лабораторных индексов в диагностике неалкогольной жировой болезни печени. Терапевтический архив. 2021;93(8):883-889 [Nosov A.E., Zenina M.T., Gorbushina O.Yu. et al. Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):883–889 (In Russian)]. DOI: 10.26442/00403660.2021.08.200973</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Allen A.M., Therneau T.M., Larson J.J. et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67(5):1726-1736. DOI:10.1002/hep.29546.</mixed-citation><mixed-citation xml:lang="en">Allen A.M., Therneau T.M., Larson J.J. et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67(5):1726-1736. DOI:10.1002/hep.29546.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Мишина Е.Е., Майоров А.Ю., Богомолов П.О. и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017;20(5):335-343 [Mishina E.E., Mayorov A.Y., Bogomolov P.O. et al. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343 (In Russian)]. DOI:10.14341/DM9372</mixed-citation><mixed-citation xml:lang="en">Мишина Е.Е., Майоров А.Ю., Богомолов П.О. и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017;20(5):335-343 [Mishina E.E., Mayorov A.Y., Bogomolov P.O. et al. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343 (In Russian)]. DOI:10.14341/DM9372</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin D., Helwig U., Pfeuffer M. et al. A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. J Hum Genet. 2006;51(6):567-574. DOI:10.1007/s10038-006-0400-y.</mixed-citation><mixed-citation xml:lang="en">Rubin D., Helwig U., Pfeuffer M. et al. A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. J Hum Genet. 2006;51(6):567-574. DOI:10.1007/s10038-006-0400-y.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Das K., Chowdhury A. Lean NASH: distinctiveness and clinical implication. Hepatol Int. 2013;7 Suppl 2:806-813. DOI:10.1007/s12072-013-9477-5.</mixed-citation><mixed-citation xml:lang="en">Das K., Chowdhury A. Lean NASH: distinctiveness and clinical implication. Hepatol Int. 2013;7 Suppl 2:806-813. DOI:10.1007/s12072-013-9477-5.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Вахрушев Я.М., Лукашевич А.П. Значение синдрома избыточного бактериального роста в нарушении метаболических функций печени при неалкогольной жировой болезни печени. Терапевтический архив. 2021;93(2): 169-173 [Vakhrushev, Y. M., &amp; Lukashevich, A. P. (2021). The importance of the bacterial overgrowth syndrome in the development of disorders metabolic functions of the liver in non-alcoholic fatty liver disease. Terapevticheskii Arkhiv, 93(2), 169-173 (In Russian)]. DOI:10.26442/00403660.2021.02.200622</mixed-citation><mixed-citation xml:lang="en">Вахрушев Я.М., Лукашевич А.П. Значение синдрома избыточного бактериального роста в нарушении метаболических функций печени при неалкогольной жировой болезни печени. Терапевтический архив. 2021;93(2): 169-173 [Vakhrushev, Y. M., &amp; Lukashevich, A. P. (2021). The importance of the bacterial overgrowth syndrome in the development of disorders metabolic functions of the liver in non-alcoholic fatty liver disease. Terapevticheskii Arkhiv, 93(2), 169-173 (In Russian)]. DOI:10.26442/00403660.2021.02.200622</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Селиверстов П.В., Джадхав С.Н., Цурцумия Д.Б. и др. Неалкогольная жировая болезнь печени: возможности диагностики. РМЖ. 2019;5:36–40 [: Seliverstov P.V., Dzhadkhav S.N., Tsurtsumia D.B. et al. Diagnostic capabilities in non-alcoholic fatty liver disease. RMJ. 2019;5:36–40 (In Russian)]. https://www.rusmedreview.com/upload/iblock/c0e/36-40.pdf [дата доступа: 10.05.2024].</mixed-citation><mixed-citation xml:lang="en">Селиверстов П.В., Джадхав С.Н., Цурцумия Д.Б. и др. Неалкогольная жировая болезнь печени: возможности диагностики. РМЖ. 2019;5:36–40 [: Seliverstov P.V., Dzhadkhav S.N., Tsurtsumia D.B. et al. Diagnostic capabilities in non-alcoholic fatty liver disease. RMJ. 2019;5:36–40 (In Russian)]. https://www.rusmedreview.com/upload/iblock/c0e/36-40.pdf [дата доступа: 10.05.2024].</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Успенская Ю.Б., Кузнецова И.В., Ведзижева Э.Р. Неалкогольная жировая болезнь печени у пациенток с синдромом поликистозных яичников. Consilium Medicum. 2016;18(6):52–58 [Uspenskaya Yu.B., Kuznetsova I.V., Vedzizheva E.R. Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome. Consilium Medicum. 2016;18(6):52–58 (In Russian)]. DOI:10.26442/2075-1753_2016.6.52-58</mixed-citation><mixed-citation xml:lang="en">Успенская Ю.Б., Кузнецова И.В., Ведзижева Э.Р. Неалкогольная жировая болезнь печени у пациенток с синдромом поликистозных яичников. Consilium Medicum. 2016;18(6):52–58 [Uspenskaya Yu.B., Kuznetsova I.V., Vedzizheva E.R. Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome. Consilium Medicum. 2016;18(6):52–58 (In Russian)]. DOI:10.26442/2075-1753_2016.6.52-58</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10):57–65 [Livzan M.A., Gaus O.V., Nikolaev N.A., Krolevetz T.S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;1(10):57-65 (In Russian)]. DOI:10.31146/1682-8658-ecg-170-10-57-65</mixed-citation><mixed-citation xml:lang="en">Ливзан М.А., Гаус О.В., Николаев Н.А., Кролевец Т.С. НАЖБП: коморбидность и ассоциированные заболевания. Экспериментальная и клиническая гастроэнтерология. 2019;170(10):57–65 [Livzan M.A., Gaus O.V., Nikolaev N.A., Krolevetz T.S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;1(10):57-65 (In Russian)]. DOI:10.31146/1682-8658-ecg-170-10-57-65</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Яфарова А.А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы. Рациональная фармакотерапия в кардиологии. 2017;13(5):645–650 [Drapkina O.M., Yafarova A.A. Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Scientific Problem State. Rational Pharmacotherapy in Cardiology 2017;13(5):645-650 (In Russian)]. DOI:10.20996/1819-6446-2017-13-5-645-650</mixed-citation><mixed-citation xml:lang="en">Драпкина О.М., Яфарова А.А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы. Рациональная фармакотерапия в кардиологии. 2017;13(5):645–650 [Drapkina O.M., Yafarova A.A. Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Scientific Problem State. Rational Pharmacotherapy in Cardiology 2017;13(5):645-650 (In Russian)]. DOI:10.20996/1819-6446-2017-13-5-645-650</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Fraser A., Harris R., Sattar N. et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007;27(12):2729-2735. DOI:10.1161/ATVBAHA.107.152298.</mixed-citation><mixed-citation xml:lang="en">Fraser A., Harris R., Sattar N. et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007;27(12):2729-2735. DOI:10.1161/ATVBAHA.107.152298.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1724-1745. DOI:10.3748/wjg.v20.i7.1724.</mixed-citation><mixed-citation xml:lang="en">Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1724-1745. DOI:10.3748/wjg.v20.i7.1724.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Руженцова Т.А. Кардиомиопатии у детей. Медицинский совет. 2014;(6):66-69 [Ruzhentsova TA. Сardiomyopathy in children. Meditsinskiy sovet = Medical Council. 2014;(6):66-69 (In Russian)]. DOI:10.21518/2079-701X-2014-6-66-69.</mixed-citation><mixed-citation xml:lang="en">Руженцова Т.А. Кардиомиопатии у детей. Медицинский совет. 2014;(6):66-69 [Ruzhentsova TA. Сardiomyopathy in children. Meditsinskiy sovet = Medical Council. 2014;(6):66-69 (In Russian)]. DOI:10.21518/2079-701X-2014-6-66-69.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Portillo-Sanchez P., Bril F., Maximos M. et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100(6):2231-2238. DOI:10.1210/jc.2015-1966.</mixed-citation><mixed-citation xml:lang="en">Portillo-Sanchez P., Bril F., Maximos M. et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100(6):2231-2238. DOI:10.1210/jc.2015-1966.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. DOI:10.1001/jama.2015.5370.</mixed-citation><mixed-citation xml:lang="en">Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. DOI:10.1001/jama.2015.5370.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ryu S., Chang Y., Jung H.S. et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2015;63(5):1229-1237. DOI:10.1016/j.jhep.2015.07.010.</mixed-citation><mixed-citation xml:lang="en">Ryu S., Chang Y., Jung H.S. et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol. 2015;63(5):1229-1237. DOI:10.1016/j.jhep.2015.07.010.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. DOI:10.1001/jama.2015.5370</mixed-citation><mixed-citation xml:lang="en">Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. DOI:10.1001/jama.2015.5370</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Eshraghian A., Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014;20(25):8102-8109. DOI:10.3748/wjg.v20.i25.8102</mixed-citation><mixed-citation xml:lang="en">Eshraghian A., Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014;20(25):8102-8109. DOI:10.3748/wjg.v20.i25.8102</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Pagadala M.R., Zein C.O., Dasarathy S. et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(2):528-534. DOI:10.1007/s10620-011-2006-2.</mixed-citation><mixed-citation xml:lang="en">Pagadala M.R., Zein C.O., Dasarathy S. et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(2):528-534. DOI:10.1007/s10620-011-2006-2.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Cheungpasitporn W., Thongprayoon C., O'Corragain O.A. et al. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton). 2014;19(12):791-797. DOI:10.1111/nep.12343.</mixed-citation><mixed-citation xml:lang="en">Cheungpasitporn W., Thongprayoon C., O'Corragain O.A. et al. Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis. Nephrology (Carlton). 2014;19(12):791-797. DOI:10.1111/nep.12343.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Pacifico L., Bonci E., Andreoli G.M. et al. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. Int J Mol Sci. 2016;17(8):1218. DOI:10.3390/ijms17081218</mixed-citation><mixed-citation xml:lang="en">Pacifico L., Bonci E., Andreoli G.M. et al. The Impact of Nonalcoholic Fatty Liver Disease on Renal Function in Children with Overweight/Obesity. Int J Mol Sci. 2016;17(8):1218. DOI:10.3390/ijms17081218</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Aron-Wisnewsky J., Minville C., Tordjman J. et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol. 2012;56(1):225-233. DOI:10.1016/j.jhep.2011.04.022.</mixed-citation><mixed-citation xml:lang="en">Aron-Wisnewsky J., Minville C., Tordjman J. et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol. 2012;56(1):225-233. DOI:10.1016/j.jhep.2011.04.022.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Musso G., Gambino R., Tabibian J.H. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. DOI:10.1371/journal.pmed.1001680.</mixed-citation><mixed-citation xml:lang="en">Musso G., Gambino R., Tabibian J.H. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. DOI:10.1371/journal.pmed.1001680.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Targher G., Lonardo A., Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. J Endocrinol Invest. 2015;38(8):817-825. DOI:10.1007/s40618-015-0315-6</mixed-citation><mixed-citation xml:lang="en">Targher G., Lonardo A., Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. J Endocrinol Invest. 2015;38(8):817-825. DOI:10.1007/s40618-015-0315-6</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Jinjuvadia R., Lohia P., Jinjuvadia C. et al. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol. 2013;47(1):33-44. DOI:10.1097/MCG.0b013e3182688c15.</mixed-citation><mixed-citation xml:lang="en">Jinjuvadia R., Lohia P., Jinjuvadia C. et al. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol. 2013;47(1):33-44. DOI:10.1097/MCG.0b013e3182688c15.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Miele L., Vallone S., Cefalo C. et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778-786. DOI:10.1016/j.jhep.2009.06.008.</mixed-citation><mixed-citation xml:lang="en">Miele L., Vallone S., Cefalo C. et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778-786. DOI:10.1016/j.jhep.2009.06.008.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758-764. DOI:10.1016/j.jhep.2009.04.020.</mixed-citation><mixed-citation xml:lang="en">Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758-764. DOI:10.1016/j.jhep.2009.04.020.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Ливзан М.А., Кролевец Т.С., Лаптева И.В., Черкащенко Н.А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014;3(4):8 14 [Livzan M.A., Korolevets T.S., Lapteva I.V., Cherkashchenko N.A. Non-alcoholic fatty liver disease in the patients presenting with abdominal obesity. Russian Journal of Evidence-Based Gastroenterology. 2014;3(4):8 14 (In Russian)]. DOI:10.17116/dokgastro2014348-14</mixed-citation><mixed-citation xml:lang="en">Ливзан М.А., Кролевец Т.С., Лаптева И.В., Черкащенко Н.А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология. 2014;3(4):8 14 [Livzan M.A., Korolevets T.S., Lapteva I.V., Cherkashchenko N.A. Non-alcoholic fatty liver disease in the patients presenting with abdominal obesity. Russian Journal of Evidence-Based Gastroenterology. 2014;3(4):8 14 (In Russian)]. DOI:10.17116/dokgastro2014348-14</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Кондратова М.А., Куимов А.Д., Максимов В.Н. и др. Мутации в гене HFE у больных неалкогольной жировой болезнью печени, особенности обменных нарушений. Экспериментальная и клиническая гастроэнтерология. 2017;145(09):18-24 [Kondratova M.A., Kuimov A.D., Maksimov V.N. et al. The frequency of HFE gene polymorphism in patients with nonalcoholic liver disease and in persons of the general population, features of metabolic disorders. Experimental and Clinical Gastroenterology Journal. 2017;145(09):18-24 (In Russian)]. http://gastrossr.org/index.php/en/2017e/e09-145 [дата доступа: 10.05.2024].</mixed-citation><mixed-citation xml:lang="en">Кондратова М.А., Куимов А.Д., Максимов В.Н. и др. Мутации в гене HFE у больных неалкогольной жировой болезнью печени, особенности обменных нарушений. Экспериментальная и клиническая гастроэнтерология. 2017;145(09):18-24 [Kondratova M.A., Kuimov A.D., Maksimov V.N. et al. The frequency of HFE gene polymorphism in patients with nonalcoholic liver disease and in persons of the general population, features of metabolic disorders. Experimental and Clinical Gastroenterology Journal. 2017;145(09):18-24 (In Russian)]. http://gastrossr.org/index.php/en/2017e/e09-145 [дата доступа: 10.05.2024].</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Богомолов П.О., Кокина К.Ю., Майоров А.Ю., Мишина Е.Е. Генетические аспекты неалкогольной жировой болезни печени. Вопросы современной педиатрии. 2018;17(6):442–448 [Bogomolov P.O., Kokina K.Yu., Mayorov A.Yu., Mishina E.E. Genetic Aspects of Non-Alcoholic Fatty Liver Disease. Current Pediatrics. 2018;17(6):442-448 (In Russian)]. DOI: 10.15690/vsp.v17i6.1974</mixed-citation><mixed-citation xml:lang="en">Богомолов П.О., Кокина К.Ю., Майоров А.Ю., Мишина Е.Е. Генетические аспекты неалкогольной жировой болезни печени. Вопросы современной педиатрии. 2018;17(6):442–448 [Bogomolov P.O., Kokina K.Yu., Mayorov A.Yu., Mishina E.E. Genetic Aspects of Non-Alcoholic Fatty Liver Disease. Current Pediatrics. 2018;17(6):442-448 (In Russian)]. DOI: 10.15690/vsp.v17i6.1974</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Speliotes E.K., Yerges-Armstrong L.M., Wu J. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324. DOI:10.1371/journal.pgen.1001324</mixed-citation><mixed-citation xml:lang="en">Speliotes E.K., Yerges-Armstrong L.M., Wu J. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324. DOI:10.1371/journal.pgen.1001324</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Бурдули А.Г., Файзуллин Л.З., Васильев Е.В. и др. Полиморфизм гена андрогенового рецептора и минеральная плотность костной ткани у женщин с аменореей. Доктор.Ру. 2012;1(69):24-27 [Burduli A.G., Faizullin L.Z., Vasiliev E.V. et al. Androgen Receptor Gene Polymorphism and Bone Mineral Density in Women with Amenorrhea. Doctor.Ru. 2012;1(69):24-27 (In Russian)]. https://cyberleninka.ru/article/n/polimorfizm-gena-androgenovogo-retseptora-i-mineralnaya-plotnost-kostnoy-tkani-u-zhenschin-s-amenoreey [дата доступа: 10.05.2024].</mixed-citation><mixed-citation xml:lang="en">Бурдули А.Г., Файзуллин Л.З., Васильев Е.В. и др. Полиморфизм гена андрогенового рецептора и минеральная плотность костной ткани у женщин с аменореей. Доктор.Ру. 2012;1(69):24-27 [Burduli A.G., Faizullin L.Z., Vasiliev E.V. et al. Androgen Receptor Gene Polymorphism and Bone Mineral Density in Women with Amenorrhea. Doctor.Ru. 2012;1(69):24-27 (In Russian)]. https://cyberleninka.ru/article/n/polimorfizm-gena-androgenovogo-retseptora-i-mineralnaya-plotnost-kostnoy-tkani-u-zhenschin-s-amenoreey [дата доступа: 10.05.2024].</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Киселева Е.В., Демидова Т.Ю. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа: проблема сопряженности и этапности развития. Ожирение и метаболизм. 2021;18(3):313-319 [Kiseleva E.V., Demidova T.Y. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obesity and metabolism. 2021;18(3):313-319 (In Russian)]. DOI:10.14341/omet12758</mixed-citation><mixed-citation xml:lang="en">Киселева Е.В., Демидова Т.Ю. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа: проблема сопряженности и этапности развития. Ожирение и метаболизм. 2021;18(3):313-319 [Kiseleva E.V., Demidova T.Y. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obesity and metabolism. 2021;18(3):313-319 (In Russian)]. DOI:10.14341/omet12758</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Petta S., Miele L., Bugianesi E. et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One. 2014;9(2):e87523. DOI:10.1371/journal.pone.0087523.</mixed-citation><mixed-citation xml:lang="en">Petta S., Miele L., Bugianesi E. et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One. 2014;9(2):e87523. DOI:10.1371/journal.pone.0087523.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Makkonen J., Pietilainen K.H., Rissanen A. et al. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol. 2009;50(5):1035–1042. DOI: 10.1016/ j.jhep.2008.12.025.</mixed-citation><mixed-citation xml:lang="en">Makkonen J., Pietilainen K.H., Rissanen A. et al. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol. 2009;50(5):1035–1042. DOI: 10.1016/ j.jhep.2008.12.025.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Guerrero R., Vega G.L., Grundy S.M. et al. Ethnic differences in hepatic steatosis: an insulin resistance paradox. Hepatology. 2009; 49(3):791–801. DOI: 10.1002/hep.22726.</mixed-citation><mixed-citation xml:lang="en">Guerrero R., Vega G.L., Grundy S.M. et al. Ethnic differences in hepatic steatosis: an insulin resistance paradox. Hepatology. 2009; 49(3):791–801. DOI: 10.1002/hep.22726.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Valenti L., Al-Serri A., Daly A.K. et al. Homozygosity, for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):1209–1217. DOI: 10.1002/hep.23622.</mixed-citation><mixed-citation xml:lang="en">Valenti L., Al-Serri A., Daly A.K. et al. Homozygosity, for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):1209–1217. DOI: 10.1002/hep.23622.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Basantani M.K., Sitnick M.T., Cai L. et al. Pnpla3/Adiponutrin defi-ciency in mice does not contribute to fatty liver disease or meta-bolic syndrome. Lipid Res. 2011;52(2):318–329. DOI: 10.1194/ jlr.M011205.</mixed-citation><mixed-citation xml:lang="en">Basantani M.K., Sitnick M.T., Cai L. et al. Pnpla3/Adiponutrin defi-ciency in mice does not contribute to fatty liver disease or meta-bolic syndrome. Lipid Res. 2011;52(2):318–329. DOI: 10.1194/ jlr.M011205.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Kumari M., Schoiswohl G., Chitraju C. et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15(5):691–702. DOI: 10.1016/j.cmet.2012.04.008.</mixed-citation><mixed-citation xml:lang="en">Kumari M., Schoiswohl G., Chitraju C. et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15(5):691–702. DOI: 10.1016/j.cmet.2012.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W., Chang B., Li L., Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010;52(3):1134–1142. DOI: 10.1002/hep.23812.</mixed-citation><mixed-citation xml:lang="en">Chen W., Chang B., Li L., Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010;52(3):1134–1142. DOI: 10.1002/hep.23812.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Bruschi F.V., Claudel T., Tardelli M. et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017;65(6):1875–1890. DOI: 10.1002/hep.29041.</mixed-citation><mixed-citation xml:lang="en">Bruschi F.V., Claudel T., Tardelli M. et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017;65(6):1875–1890. DOI: 10.1002/hep.29041.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Valenti L., Rumi M., Galmozzi E. et al. Patatin-like phospholi-pase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53(3):791–799. DOI: 10.1002/hep.24123.</mixed-citation><mixed-citation xml:lang="en">Valenti L., Rumi M., Galmozzi E. et al. Patatin-like phospholi-pase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53(3):791–799. DOI: 10.1002/hep.24123.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Kozlitina J., Smagris E., Stender S. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–356. DOI:10.1038/ng.2901</mixed-citation><mixed-citation xml:lang="en">Kozlitina J., Smagris E., Stender S. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–356. DOI:10.1038/ng.2901</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Petta S., Miele L., Bugianesi E. et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in nonalcoholic fatty liver disease. PLoS One. 2014;9(2):e87523. DOI: 10.1371/journal. pone.0087523.</mixed-citation><mixed-citation xml:lang="en">Petta S., Miele L., Bugianesi E. et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in nonalcoholic fatty liver disease. PLoS One. 2014;9(2):e87523. DOI: 10.1371/journal. pone.0087523.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A. 2014;111(24):8913-8918. DOI:10.1073/pnas.1323785111.</mixed-citation><mixed-citation xml:lang="en">Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A. 2014;111(24):8913-8918. DOI:10.1073/pnas.1323785111.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y.L., Reeves H.L., Burt A.D. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with nonalcoholic fatty liver disease. Nat Commun. 2014;5:4309. DOI:10.1038/ncomms5309.</mixed-citation><mixed-citation xml:lang="en">Liu Y.L., Reeves H.L., Burt A.D. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with nonalcoholic fatty liver disease. Nat Commun. 2014;5:4309. DOI:10.1038/ncomms5309.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Milano M., Aghemo A., Mancina R.M. et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62(1):111–117. DOI:10.1002/hep.27811</mixed-citation><mixed-citation xml:lang="en">Milano M., Aghemo A., Mancina R.M. et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62(1):111–117. DOI:10.1002/hep.27811</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Speliotes E.K., Yerges-Armstrong L.M., Wu J. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324. DOI: 10.1371/journal.pgen.1001324</mixed-citation><mixed-citation xml:lang="en">Speliotes E.K., Yerges-Armstrong L.M., Wu J. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324. DOI: 10.1371/journal.pgen.1001324</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Beer N.L., Tribble N.D., McCulloch L.J. et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18(21):4081–4088. DOI:10.1093/hmg/ddp357.</mixed-citation><mixed-citation xml:lang="en">Beer N.L., Tribble N.D., McCulloch L.J. et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18(21):4081–4088. DOI:10.1093/hmg/ddp357.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Santoro N., Zhang C.K., Zhao H. et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55(3):781–789. DOI:10.1002/hep.24806.</mixed-citation><mixed-citation xml:lang="en">Santoro N., Zhang C.K., Zhao H. et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55(3):781–789. DOI:10.1002/hep.24806.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Пальцев И.В., Калинин А.Л. Мутации гена HFE как фактор риска развития гемохроматоза у больных хроническими диффузными заболеваниями печени. Проблемы здоровья и экологии. 2010;(4):53-57 [Paltsev I.V., Kalinin A.L. M utations of gene HFE as a risk factor of hemochromatosis development at patient with chronic diffuse liver diseases. Health and Ecology Issues. 2010;(4):53-57 (In Russian)]. DOI:10.51523/2708-6011.2010-7-4-10</mixed-citation><mixed-citation xml:lang="en">Пальцев И.В., Калинин А.Л. Мутации гена HFE как фактор риска развития гемохроматоза у больных хроническими диффузными заболеваниями печени. Проблемы здоровья и экологии. 2010;(4):53-57 [Paltsev I.V., Kalinin A.L. M utations of gene HFE as a risk factor of hemochromatosis development at patient with chronic diffuse liver diseases. Health and Ecology Issues. 2010;(4):53-57 (In Russian)]. DOI:10.51523/2708-6011.2010-7-4-10</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнова О.В., Лагутинская Д.В. Полиморфизмы генов HSD17B13, GCKR, HFE и CP как факторы развития неалкогольной жировой болезни печени и сопутствующих ее заболеваний. Медицинский Совет. 2023;(8):119-125 [Smirnova O.V., Lagutinskaya D.V. Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases. Meditsinskiy sovet = Medical Council. 2023;(8):119-125 (In Russian)]. DOI:10.21518/ms2022-026.</mixed-citation><mixed-citation xml:lang="en">Смирнова О.В., Лагутинская Д.В. Полиморфизмы генов HSD17B13, GCKR, HFE и CP как факторы развития неалкогольной жировой болезни печени и сопутствующих ее заболеваний. Медицинский Совет. 2023;(8):119-125 [Smirnova O.V., Lagutinskaya D.V. Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases. Meditsinskiy sovet = Medical Council. 2023;(8):119-125 (In Russian)]. DOI:10.21518/ms2022-026.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Ахмедов В.А., Меликов Т.И. Генетические аспекты формирования неалкогольной жировой болезни печени. Лечащий врач. 2019;8:28-31 [Akhmedov V.A., Melikov T.I. Genetic aspects of the formation of non-alcoholic fatty liver disease. Lechashchiy vrach. 2019;8:28-31 (In Russian)]. DOI:10.26295/OS.2019.70.74.004</mixed-citation><mixed-citation xml:lang="en">Ахмедов В.А., Меликов Т.И. Генетические аспекты формирования неалкогольной жировой болезни печени. Лечащий врач. 2019;8:28-31 [Akhmedov V.A., Melikov T.I. Genetic aspects of the formation of non-alcoholic fatty liver disease. Lechashchiy vrach. 2019;8:28-31 (In Russian)]. DOI:10.26295/OS.2019.70.74.004</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Шулькина С.Г., Эрбес П.Э., Смирнова Е.Н. Значение полиморфизма генов ММР12 (rs652483) И PPARG (rs1801282) в формировании неалкогольной жировой болезни печени у женщин с ожирением. Терапия. 2022;10:79-88 [Shulkina S.G., Erbes P.E., Smirnova E.N. The significance of polymorphism of the MMP12 (rs652483) and PPARG (rs1801282) genes in the formation of non-alcoholic fatty liver disease in obese women. Therapy. 2022;10:79-88 (In Russian)]. DOI:10.18565/therapy.2022.10.79-88</mixed-citation><mixed-citation xml:lang="en">Шулькина С.Г., Эрбес П.Э., Смирнова Е.Н. Значение полиморфизма генов ММР12 (rs652483) И PPARG (rs1801282) в формировании неалкогольной жировой болезни печени у женщин с ожирением. Терапия. 2022;10:79-88 [Shulkina S.G., Erbes P.E., Smirnova E.N. The significance of polymorphism of the MMP12 (rs652483) and PPARG (rs1801282) genes in the formation of non-alcoholic fatty liver disease in obese women. Therapy. 2022;10:79-88 (In Russian)]. DOI:10.18565/therapy.2022.10.79-88</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Королева Е.И., Назаров В.Д., Лапин С.В. и др. Генетические аспекты неклассической формы врожденной гиперплазии коры надпочечников: литературный обзор и собственный опыт. Молекулярная медицина. 2020;18(3):11–19 [Koroleva E.I., Nazarov V.D., Lapin S.V. et al. Genetic aspects of the non-classical form of congenital adrenal hyperplasia: literature review and personal experience. Molecular medicine. 2020;18(3):11–19 (In Russian)]. DOI:10.29296/24999490-2020-03-02</mixed-citation><mixed-citation xml:lang="en">Королева Е.И., Назаров В.Д., Лапин С.В. и др. Генетические аспекты неклассической формы врожденной гиперплазии коры надпочечников: литературный обзор и собственный опыт. Молекулярная медицина. 2020;18(3):11–19 [Koroleva E.I., Nazarov V.D., Lapin S.V. et al. Genetic aspects of the non-classical form of congenital adrenal hyperplasia: literature review and personal experience. Molecular medicine. 2020;18(3):11–19 (In Russian)]. DOI:10.29296/24999490-2020-03-02</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Carmina E., Dewailly D., Escobar-Morreale H.F. et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update. 2017;23(5):580-599. DOI:10.1093/humupd/dmx014.</mixed-citation><mixed-citation xml:lang="en">Carmina E., Dewailly D., Escobar-Morreale H.F. et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update. 2017;23(5):580-599. DOI:10.1093/humupd/dmx014.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Беглова А.Ю., Елгина С.И., Гордеева Л.А. Полиморфизм генов CYP11A1, CYP17, CYP19 у женщин репродуктивного возраста с синдромом поликистозных яичников. Акушерство и гинекология. 2019;12:148-153 [Beglova A.Yu., Elgina S.I., Gordeeva L.A Polymorphism of the CYP11A1, CYP17A1, and CYP19A1 genes in reproductive-aged women with polycystic ovary syndrome. Obstetrics and Gynegology. 2019;12:148-153 (In Russian)]. DOI:10.18565/aig.2019.12.148-153</mixed-citation><mixed-citation xml:lang="en">Беглова А.Ю., Елгина С.И., Гордеева Л.А. Полиморфизм генов CYP11A1, CYP17, CYP19 у женщин репродуктивного возраста с синдромом поликистозных яичников. Акушерство и гинекология. 2019;12:148-153 [Beglova A.Yu., Elgina S.I., Gordeeva L.A Polymorphism of the CYP11A1, CYP17A1, and CYP19A1 genes in reproductive-aged women with polycystic ovary syndrome. Obstetrics and Gynegology. 2019;12:148-153 (In Russian)]. DOI:10.18565/aig.2019.12.148-153</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Pizzuti A., Frittitta L., Argiolas A. et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999;48(9):1881-1884. DOI:10.2337/diabetes.48.9.1881.</mixed-citation><mixed-citation xml:lang="en">Pizzuti A., Frittitta L., Argiolas A. et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999;48(9):1881-1884. DOI:10.2337/diabetes.48.9.1881.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Böttcher Y., Körner A., Reinehr T. et al. ENPP1 variants and haplotypes predispose to early onset obesity and impaired glucose and insulin metabolism in German obese children. J Clin Endocrinol Metab. 2006;91(12):4948-52. DOI: 10.1210/jc.2006-0540.</mixed-citation><mixed-citation xml:lang="en">Böttcher Y., Körner A., Reinehr T. et al. ENPP1 variants and haplotypes predispose to early onset obesity and impaired glucose and insulin metabolism in German obese children. J Clin Endocrinol Metab. 2006;91(12):4948-52. DOI: 10.1210/jc.2006-0540.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Cuchel M., Bloedon L.T., Szapary P.O. et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 11;356(2):148-56. DOI:10.1056/NEJMoa061189.</mixed-citation><mixed-citation xml:lang="en">Cuchel M., Bloedon L.T., Szapary P.O. et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 11;356(2):148-56. DOI:10.1056/NEJMoa061189.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Shali K., Wang J., Rosen F., Hegele R.A. Ileal adenocarcinoma in a mild phenotype of abetalipoproteinemia. Clin Genet. 2003;63(2):135-8. DOI: 10.1046/j.0009-9163.2002.00175.x.</mixed-citation><mixed-citation xml:lang="en">Al-Shali K., Wang J., Rosen F., Hegele R.A. Ileal adenocarcinoma in a mild phenotype of abetalipoproteinemia. Clin Genet. 2003;63(2):135-8. DOI: 10.1046/j.0009-9163.2002.00175.x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
